TNYA stock forecast, quote, news & analysis
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease... Show more
Why Tenaya Therapeutics (TNYA) Stock Is Down -32% in the Last 30 Days
Key Takeaways
- Tenaya Therapeutics (TNYA) fell roughly 32% over the last 30 days, declining from about $0.57 to near $0.38 per share.
- The selloff was driven primarily by a clinical hold on the TN-201 (MyPEAK-1) trial and a proposed reverse stock split.
- Nasdaq minimum bid price compliance concerns, with shares trading below $1.00, compounded investor anxiety.
- A positive FDA Regenerative Medicine Advanced Therapy (RMAT) designation for TN-401 was overshadowed by the negative news.
- Third-quarter 2026 results beat consensus estimates but were not enough to reverse bearish sentiment.
- Management reiterated a cash runway into the fourth quarter of 2027, with about $66.8 million in cash and equivalents as of September 30, 2026.
- For deeper detail on valuation and expectations, explore Price Targets, Earnings, and Forecast pages for TNYA.
- Investors tracking automated strategies can also explore Trending AI Robots for data-driven trading ideas.
Tenaya Therapeutics (TNYA) Company Overview and Market Position
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on discovering and developing potentially curative therapies for heart disease. Its pipeline centers on cardiac gene therapy and includes TN-201, an AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy; TN-401, an AAV9-based gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a small-molecule HDAC6 inhibitor for heart failure with preserved ejection fraction. The company also holds a research collaboration with Alnylam Pharmaceuticals (ALNY) to identify and validate novel gene targets in cardiovascular disease, an agreement worth up to roughly $1.13 billion in potential milestone payments. Because Tenaya is pre-revenue and its valuation depends heavily on clinical and regulatory outcomes, investors follow the stock closely for pipeline data readouts and capital adequacy signals.
Tenaya Therapeutics (TNYA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, TNYA shares declined approximately 32%, falling from a closing price near $0.57 to roughly $0.38. The sharpest move occurred in a single session in mid-October, when the stock dropped about 25% on unusually heavy volume exceeding 12 million shares. The broader three-month trend has been similarly weak, with the stock down roughly 49% over the last quarter as it slid from the low-$0.70s to its current level. This persistent downtrend has left the shares trading near the lower end of their 52-week range and below the $1.00 threshold, reinforcing technical and compliance-related pressure on the name.
What Drove TNYA Stock Price in the Last 30 Days
The recent decline was driven by company-specific regulatory and capital-structure concerns rather than a broad sector selloff. In early October, the company disclosed that the MyPEAK-1 Phase 1b/2 trial of its lead candidate TN-201 had been placed on clinical hold by the U.S. Food and Drug Administration. Management stated it was preparing a protocol amendment to standardize patient monitoring and immunosuppressive regimen management and expressed confidence the hold would not affect long-term data milestones, but investors reacted sharply to the added uncertainty.
Around the same time, Tenaya filed a preliminary proxy statement seeking shareholder approval for a reverse stock split at a ratio between 1-for-10 and 1-for-25, with the exact ratio left to the board's discretion. The proposal is tied to Nasdaq listing compliance: the company received a minimum bid price notice in January 2026 and later transferred to the Nasdaq Capital Market, with a compliance period running into January 2027. The reverse-split proposal, combined with a sub-$1.00 share price and continued cash burn, amplified concerns about dilution and delisting risk.
These negatives overshadowed a genuine positive: in mid-September, the FDA granted RMAT designation to TN-401 for PKP2-associated ARVC, supported by interim RIDGE-1 data showing reduced arrhythmia burden. Third-quarter 2026 results also beat expectations, with an EPS loss of $0.08 versus a roughly $0.10 consensus loss and collaboration revenue of $1.7 million versus about $0.8 million expected.
What Drove TNYA Stock Performance Over the Last Quarter
The multi-month decline reflects a combination of regulatory setbacks, listing-compliance pressure, and persistent pre-revenue cash burn. A second-quarter 2026 loss that included a sizable non-cash manufacturing-facility impairment charge weighed on sentiment earlier in the period, and the subsequent clinical hold on TN-201 extended the uncertainty into the autumn. The proposed reverse stock split crystallized investor fears about the stock's sub-$1.00 status. Even favorable pipeline milestones, such as the RMAT designation for TN-401 and a strengthened cash position supported in part by the Alnylam collaboration, failed to offset the risk-off posture toward this small-cap, clinical-stage name.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's algorithmic trading tools. Tickeron offers hundreds of AI-driven trading bots that monitor thousands of tickers, but only the top-performing and most relevant strategies appear in this featured section. These bots differ in trading strategy, holding timeframe, and performance metrics, giving users a way to compare approaches suited to varying risk tolerances and market conditions. For investors seeking a data-driven complement to traditional research, exploring the Trending AI Robots section can provide additional perspective on current market opportunities.
TNYA Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors are likely to shape TNYA. The outcome of the December 2026 special meeting on the reverse stock split proposal, and any related Nasdaq listing-compliance updates, will be closely watched. Investors should also monitor resolution of the TN-201 clinical hold and additional data and regulatory updates on TN-201, TN-401, and TN-301, which management has indicated are expected in the fourth quarter of 2026. Capital management will remain central, given the company's pre-revenue status and the need to fund its pipeline into pivotal-trial planning. Analyst sentiment remains broadly positive, with a Strong Buy consensus and average price targets well above the current price, but individual firms have been trimming their targets. As always, these are informational considerations and not investment recommendations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TNYA sees its Stochastic Oscillator climbs out of oversold territory
On November 09, 2026, the Stochastic Oscillator for TNYA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In 53 of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TNYA's RSI Oscillator exited the oversold zone, 33 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for TNYA just turned positive on October 28, 2026. Looking at past instances where TNYA's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +24.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNYA advanced for three days, in 210 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
TNYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TNYA as a result. In 73 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TNYA entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.164) is normal, around the industry mean (3.498). P/E Ratio (-0.706) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (94.340) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. TNYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology